Prognosis of pulmonary arterial hypertension: The power of clinical registries of rare diseases

Circulation

Volumn 122, Issue 2, 2010, Pages 106-108

  McLaughlin, Vallerie V ^a   Suissa, Samy ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Editorials; Prognosis; Pulmonary heart disease; Pulmonary hypertension; Registries; Survival

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

AGE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE REGISTRY; EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HEREDITY; HUMAN; IDIOPATHIC DISEASE; KIDNEY FAILURE; LUNG DIFFUSION CAPACITY; LUNG VASCULAR RESISTANCE; MORTALITY; PERICARDIAL EFFUSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RARE DISEASE; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; WALKING;

ADULT; AGED; CARDIAC OUTPUT; FEMALE; FOLLOW-UP STUDIES; GENETIC DISEASES, INBORN; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

EID: 77954761782     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.963983     Document Type: Editorial

References (13)

1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
2. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334: 296-301. (Pubitemid 26033085)
3. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915-1922.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaï ci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:156-163.
5. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan D, Jaïs X, Parent F, Savale L, Delphin N, Sven G, Chaouat A, Chabot F, Cordier J, Jing Z, Souza R, Simmoneau G. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur Respir J. In press.
6. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-172.
7. Benza RL, Miller DP, Gomberg-Maitland M, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. Use of the REVEAL pulmonary arterial hypertension (PAH) risk score calculator in newly diagnosed patients. Am J Respir Crit Care Med. 2010;181:A2510.
8. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
9. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106: 1477-1482.
11. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53:1573-1619.
12. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P; Document Reviewers, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
13. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376-387.